30 closest matches · ranked by relevance
BK Virus (BKV) Viremia
Primary: Incidence of BKV Viremia in the Study Population of Screened Renal or Renal-pancreas Transplant Subjects — 58 Participants
BK Virus Infection
Primary: Number of Patients Developing BK Infection at 6 Months Post-transplant — 25; 5 Participants
BK Viremia · BK Nephropathy
Primary: Number of Participants With BK Viral Load <600 Copies/mL — 13; 17 Participants
HIV · Salivary Gland Disease · Benign Lymphoepithelial Lesion
Primary: BK Viral Status in Saliva at Week 4 — 3; 6; 5; 1 Participants
Viruria
Primary: Number of Adverse Events in Post-Transplant Patients With BK Virus Viruria — 1; 1; 1; 2 Participants
BK Viremia
Primary: Percent Change From Baseline in BK Virus Copies at 3 Months — 70.3; 69.1 Percent change of BK virus copies
BK Virus Nephropathy · BK Virus Infection
Primary: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) — 17; 17; 16 Participants
Renal Transplant Infection
Primary: Participants Will Experience Less BK Infection Episodes Based on Viruria Results.
BK Virus Infection
Primary: Evidence of Reduction of BK Viruria and/or Clearance of BK Viremia — 11; 8 participants — p=0.53
BK Virus Infection
Primary: Time (Weeks) to Decrease of BKV Plasma Viral Load by 1 Log — 19.61; 10.80; 18.25 Weeks — p=0.1866
Disease Due to BK Polyomavirus · Kidney Transplant Infection
Primary: Occurrence of BK Viruria — 22; 26 Participants
Highly-sensitized Kidney Transplant Recipients
Primary: The Number of Polyoma BK Viremia Patients — 5 Participants
Nephrotoxicity
Primary: Change From Baseline in Serum Estimated Glomerular Filtration Rate (eGFR) — 2.25 ml/min/1.73m2
Post-transplant Lymphoproliferative Disease · Solid Organ Transplant · Stem Cell Transplant (Bone Marrow Transplant)
Primary: Overall Response Rate — 3 Participants
Organ Transplantation
Primary: Number of Patients Successfully Withdrawn From Oral Immunosuppression — 12; 7 Participants
Renal Interstitial Fibrosis
Primary: Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population — 26; 31; 12; 16 Participants
Viral Infection
Primary: Number of Participants With a DLT — 0; 0; 0; 3 Participants
Transplantation Infection · Epstein-Barr Virus Infections · Cytomegalovirus Infections
Primary: Compare Incidence, Duration and Magnitude of CMV and EBV Viremia in Kidney Transplant Recipients Receiving valA vs. valG. — 16; 20; 8; 4 Participants
Failing Renal Allograft
Primary: Number of Participants With Donor-specific Antibody Formation — 3; 4 Participants
Polycystic Kidney, Autosomal Dominant
Primary: Change From Baseline (CFB) in Total Kidney Volume (TKV) at Month 25 — 1686.38; 1418.96; 1487.48; 1670.33 centimeter cube (cm^3) — p=<0.0001
Proteinuria
Primary: Change in Proteinuria by 25% — 8 Participants
Kidney Transplantation · Vitamin D Deficiency
Primary: Compare Efficacy and Safety of Two Vitamin D Supplements of These Doses in Normalizing Vitamin D Concentrations. — 8; 29 ng/ml
Cytomegalovirus Disease
Primary: Incidence of CMV Disease or CMV Viremia — 29; 9; 26 Participants
Kidney, Polycystic, Autosomal Dominant
Primary: Change in Urine cAMP Concentration and Urine Osmolality (UOsm) — -2.6; -2.0 fold change in cAMP/UOsm (umol/UOsm)
Acute Graft Rejection · Chronic Allograft Nephropathy · Polyomavirus-related Transplant Nephropathy
Primary: Patient Survival — 96.4; 96.3 percentage of participants
Adenovirus Infection · BK Virus Infection · Cytomegalovirus Infections
Primary: Number of Participants Experiencing Clinically Significant Infections or Episodes of End-organ Disease — 3 Participants
Infection
Primary: Number of Patients Where a Suitable VST Line Could be Found — 80 Participants
Cytomegalovirus (CMV) Infection · Kidney Transplantation
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 6; 3; 23; 12 Participants
Antibody-mediated Rejection · Kidney Transplant; Complications · Transplant Glomerulopathy
Primary: Number of Participants With Donor Specific Antibody (DSA) Elimination or Reduction Based on Luminex HLA Testing — 7 Participants
Kidney Transplantation · Primary Focal Segmental Glomerulosclerosis (FSGS)
Primary: Percentage of Participants With Recurrence of Focal Segmental Glomerulosclerosis (rFSGS) or Death or Graft Loss or Lost to Follow-up Through 3 Months Post Transplant…